Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
M05BX07
|
| gptkbp:developedBy |
gptkb:Kyowa_Kirin
gptkb:Ultragenyx_Pharmaceutical |
| gptkbp:genericName |
gptkb:burosumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Crysvita
|
| gptkbp:indication |
adult patients with X-linked hypophosphatemia
pediatric patients with X-linked hypophosphatemia tumor-induced osteomalacia in adults |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:fibroblast_growth_factor_23
|
| gptkbp:mechanismOfAction |
FGF23 inhibitor
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:usedFor |
gptkb:X-linked_hypophosphatemia
gptkb:tumor-induced_osteomalacia |
| gptkbp:bfsParent |
gptkb:Kyowa_Kirin
gptkb:Ultragenyx_Pharmaceutical gptkb:Ultragenyx gptkb:Kyowa_Hakko_Kirin |
| gptkbp:bfsLayer |
7
|